Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
OXYCONTIN vs MYCOPHENOLATE SODIUM
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Oxycodone is a full opioid agonist with relative selectivity for the mu-opioid receptor, although it can bind to other opioid receptors at higher doses. The principal therapeutic action of oxycodone is analgesia. Like all full opioid agonists, there is no ceiling effect for analgesia with oxycodone. Clinically, dosage is titrated to provide adequate analgesia and may be limited by adverse reactions, including respiratory and CNS depression.
Mycophenolate sodium is a prodrug that is hydrolyzed to mycophenolic acid (MPA), a reversible inhibitor of inosine monophosphate dehydrogenase (IMPDH). IMPDH is a key enzyme in the de novo synthesis of guanine nucleotides, which is crucial for T- and B-lymphocyte proliferation. MPA preferentially inhibits the type II isoform of IMPDH expressed in activated lymphocytes, thereby exerting immunosuppressive effects.
Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate,Off-label: Treatment of opioid dependence (as part of substitution therapy)
Prophylaxis of organ rejection in renal transplant patients receiving cyclosporine and corticosteroids,Prophylaxis of organ rejection in cardiac transplant patients (off-label),Prophylaxis of organ rejection in hepatic transplant patients (off-label),Treatment of lupus nephritis (off-label)
10 mg orally every 12 hours; titrate based on pain severity and prior opioid exposure.
720 mg orally twice daily, administered as two 360 mg tablets or two 180 mg capsules. Intravenous infusion: 720 mg intravenously over 2 hours twice daily, for patients unable to tolerate oral therapy.
4.5-5.0 hours (immediate-release); controlled-release OXYCONTIN has an apparent half-life of 4.5-8.7 hours. Terminal half-life is ~3.5-4 hours for immediate-release, reflecting context-sensitive elimination.
The terminal elimination half-life of mycophenolic acid is approximately 8-16 hours in healthy subjects and renal transplant patients. The half-life of the inactive glucuronide metabolite (MPAG) is longer (16-18 hours) and accumulates in renal impairment.
Oxycodone is metabolized primarily via CYP3A4 to noroxycodone (major metabolite) and via CYP2D6 to oxymorphone (minor metabolite). Both metabolites are active, with oxymorphone having higher potency. Oxycodone and its metabolites are conjugated and excreted in urine.
Mycophenolate sodium is a prodrug that is rapidly hydrolyzed in the gastrointestinal tract to the active metabolite mycophenolic acid (MPA). MPA is primarily metabolized by uridine diphosphate-glucuronosyltransferase (UGT) 1A9 to the inactive phenolic glucuronide (MPAG). A minor acyl glucuronide metabolite is also formed. MPAG is excreted in the urine and can be deconjugated back to MPA via enterohepatic recirculation.
Primarily renal (90% as metabolites, 10% unchanged). Also biliary/fecal (10%).
Mycophenolate sodium is excreted primarily in urine as mycophenolic acid (MPA) and its glucuronide metabolite (MPAG). Renal excretion accounts for approximately 87% of the dose, with <1% excreted as unchanged MPA. Fecal excretion represents about 6%.
38-45%, primarily bound to albumin.
Mycophenolic acid is 97% bound to serum albumin. The glucuronide metabolite (MPAG) is 82% bound.
2.6-3.0 L/kg. Extensive tissue distribution, high Vd indicates penetration into peripheral tissues.
The apparent volume of distribution of mycophenolic acid is approximately 3.6 L/kg, indicating extensive tissue distribution. This large Vd reflects high tissue binding and distribution into extravascular spaces.
Oral immediate-release: 60-87% (first-pass metabolism). Oral extended-release (Oxy Contin): 60-87% (similar). Intravenous: 100%.
The oral bioavailability of mycophenolate sodium enteric-coated tablets is approximately 72% relative to intravenous mycophenolate mofetil. Food reduces peak concentration (Cmax) by 30-50% but does not significantly affect total area under the curve (AUC).
Cr Cl 30-60 m L/min: reduce dose by 25%; Cr Cl <30 m L/min: reduce dose by 50% and administer every 12 hours; hemodialysis: avoid use.
For GFR 15-29 m L/min/1.73 m2: do not exceed 720 mg orally twice daily. For GFR <15 m L/min/1.73 m2: no data; use with caution. No adjustment for GFR >=30 m L/min/1.73 m2.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 50%; Child-Pugh Class C: avoid use.
No specific dose adjustment guidelines for Child-Pugh class A, B, or C. Use with caution in severe hepatic impairment due to limited data.
Not approved for pediatric patients <18 years; for children ≥11 years (opioid-tolerant): 0.2 mg/kg orally every 12 hours, titrate; maximum single dose 10 mg.
Approved for pediatric renal transplant patients >=2 years: 400 mg/m2 orally twice daily (up to a maximum of 720 mg twice daily). For bone marrow transplant patients >=2 years: 400 mg/m2 orally twice daily, starting 24 hours after graft infusion.
Initiate at 5 mg orally every 12 hours; titrate cautiously; monitor for respiratory depression and constipation.
No specific dose adjustment recommended; elderly patients may have increased risk of adverse effects such as gastrointestinal hemorrhage and infections. Use the lowest effective dose and monitor renal function closely.
WARNING: ADDICTION, ABUSE, AND MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION; NEONATAL OPIOID WITHDRAWAL SYNDROME; and RISKS FROM CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS
Increased risk of congenital malformations and first-trimester pregnancy loss when used during pregnancy. Females of reproductive potential must be counseled about pregnancy prevention and planning. Mycophenolate can cause fetal harm when administered to a pregnant woman. Use is contraindicated in women of childbearing potential who are not using highly effective contraception.
Addiction, abuse, and misuse: Oxy Contin exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death. Assess each patient's risk prior to prescribing, and monitor all patients regularly for the development of these behaviors or conditions.,Life-threatening respiratory depression: Serious, life-threatening, or fatal respiratory depression may occur. Monitor for respiratory depression, especially during initiation of therapy or following a dose increase. Instruct patients to swallow tablets whole; crushing, chewing, or dissolving can cause rapid release and absorption of a potentially fatal dose.,Accidental ingestion: Accidental ingestion of even one dose of Oxy Contin, especially by children, can result in a fatal overdose of oxycodone.,Neonatal opioid withdrawal syndrome: Prolonged use of Oxy Contin during pregnancy can result in withdrawal in the neonate. Neonatal opioid withdrawal syndrome, unlike opioid withdrawal in adults, may be life-threatening if not recognized and treated.,Risks from concomitant use with benzodiazepines or other CNS depressants: Concomitant use of opioids with benzodiazepines or other CNS depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing for use in patients for whom alternative treatment options are inadequate.
Immunosuppression: Increased susceptibility to infections, including opportunistic infections and reactivation of latent viruses (e.g., CMV, BK virus).,Lymphoproliferative disorders: Increased risk of post-transplant lymphoproliferative disorder (PTLD) and other malignancies.,Pregnancy: Associated with first-trimester pregnancy loss and congenital malformations; contraception counseling required.,Gastrointestinal events: Severe GI bleeding, perforation, and ulceration; monitor for symptoms.,Neutropenia: Can cause severe neutropenia; monitor complete blood counts regularly.,Vaccinations: Live vaccines should not be given during treatment; influenza vaccination may be less effective.
Significant respiratory depression,Acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment,Known or suspected gastrointestinal obstruction, including paralytic ileus,Hypersensitivity (e.g., anaphylaxis) to oxycodone or any other components of the product
Hypersensitivity to mycophenolate sodium, mycophenolic acid, or any component of the formulation,Women of childbearing potential not using highly effective contraception,Pregnancy (unless no suitable alternative immunosuppressant is available)
Avoid alcohol, which can increase oxycodone absorption and central nervous system depression. Grapefruit juice may alter oxycodone metabolism; limit or avoid consumption. No specific food restrictions, but high-fat meals may slow absorption slightly; take with or without food consistently.
Take on an empty stomach (1 hour before or 2 hours after meals) to minimize variability. Avoid grapefruit juice (may increase mycophenolate exposure). No specific dietary restrictions other than consistent timing relative to meals. High-fat meals reduce Cmax and AUC; administer consistently with or without food.
FDA Pregnancy Category C prior to 2020; no adequate studies in pregnant women. First trimester: Limited data suggest possible increased risk of neural tube defects (1.8-fold) and oral clefts (1.5-fold) with opioid use, but confounded by underlying conditions. Second and third trimesters: Chronic use may cause fetal opioid dependence and neonatal abstinence syndrome (NAS); maternal withdrawal may precipitate preterm labor. Avoid prolonged use near term due to risk of neonatal respiratory depression.
First trimester: High risk of structural malformations (e.g., cleft lip/palate, microtia, congenital heart defects) and spontaneous abortion. Second and third trimesters: Risk of oligohydramnios, intrauterine growth restriction, and preterm birth. Use is contraindicated in pregnancy unless no alternative.
Oxycodone is excreted into breast milk; relative infant dose is approximately 2.7–8.8% of maternal weight-adjusted dose. M/P ratio unknown. Monitor infant for sedation, respiratory depression, and poor feeding. American Academy of Pediatrics considers oxycodone compatible with breastfeeding with caution; avoid rapid accumulation in mothers with impaired metabolism (CYP2D6 poor metabolizers).
Enters breast milk; M/P ratio not established. Potential for serious adverse effects in nursing infants (e.g., immunosuppression, gastrointestinal disturbances). Contraindicated during breastfeeding.
Pregnancy increases oxycodone clearance by 1.3- to 2.5-fold due to enhanced hepatic metabolism (CYP3A4 and CYP2D6 induction) and increased renal blood flow. Dose adjustments may be necessary to maintain analgesia; clinical monitoring for pain control and withdrawal symptoms is essential. Titrate to effect; avoid abrupt discontinuation. Postpartum clearance returns to baseline over 1-2 weeks.
Pharmacokinetic changes (increased clearance, decreased absorption) may require higher doses to maintain therapeutic levels; therapeutic drug monitoring recommended. Postpartum doses may need reduction due to changed pharmacokinetics.
Oxy Contin is an extended-release formulation of oxycodone, indicated for around-the-clock pain management. Do not crush, chew, or break tablets, as this can lead to rapid release and fatal overdose. Use with caution in patients with respiratory compromise, head injury, or increased intracranial pressure. Monitor for signs of misuse, abuse, or addiction. Abrupt discontinuation may precipitate withdrawal; taper dose gradually. Constipation is common; consider prophylactic laxatives. Contraindicated in severe asthma, paralytic ileus, or hypersensitivity.
Monitor CBC weekly during first month, then biweekly for second and third months, then monthly for first year. Consider therapeutic drug monitoring (AUC 30-60 mg·h/L) to optimize dosing and reduce toxicity. Delayed-release formulation (Myfortic) must not be crushed or chewed. Avoid concurrent antacids or bile acid sequestrants. Dose reduction required in renal impairment (e GFR <50 m L/min). Estimate using ideal body weight. Taper when discontinuing to avoid graft rejection.
Take Oxy Contin exactly as prescribed, usually every 12 hours. Do not take more or less than directed.,Swallow the tablet whole with water. Do not crush, chew, or break the tablet, as this can cause a dangerous overdose.,Avoid alcohol and other central nervous system depressants (e.g., benzodiazepines, sedatives) as they increase the risk of severe sedation, respiratory depression, and death.,Do not stop taking Oxy Contin suddenly; ask your doctor how to safely discontinue the medication to avoid withdrawal symptoms.,Common side effects include constipation, nausea, drowsiness, and dizziness. Contact your doctor if you experience severe constipation, difficulty breathing, or signs of allergic reaction.,Store Oxy Contin in a secure place out of sight and reach of children and pets. Dispose of unused medication via a drug take-back program.,Do not drive or operate heavy machinery until you know how Oxy Contin affects you.,Inform all healthcare providers that you are taking Oxy Contin, especially before surgery or emergency treatment.
Take exactly as prescribed; do not stop or change dose without consulting your transplant team.,Swallow delayed-release tablets whole; do not crush, chew, or cut them.,Use reliable contraception before, during, and for 6 weeks after treatment for females; males should use condoms during and for 90 days after treatment.,Avoid live vaccines (e.g., MMR, varicella) and close contact with recently vaccinated individuals.,Report signs of infection (fever, sore throat, chills), unexplained bruising/bleeding, or GI symptoms (nausea, diarrhea, abdominal pain).,Take on an empty stomach (1 hour before or 2 hours after meals) for consistent absorption.,Avoid grapefruit juice as it may alter drug levels.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about OXYCONTIN vs MYCOPHENOLATE SODIUM, answered by our medical review team.
OXYCONTIN is a Opioid Analgesic that works by Oxycodone is a full opioid agonist with relative selectivity for the mu-opioid receptor, although it can bind to other opioid receptors at higher doses. The principal therapeutic action of oxycodone is analgesia. Like all full opioid agonists, there is no ceiling effect for analgesia with oxycodone. Clinically, dosage is titrated to provide adequate analgesia and may be limited by adverse reactions, including respiratory and CNS depression.. MYCOPHENOLATE SODIUM is a Immunosuppressant that works by Mycophenolate sodium is a prodrug that is hydrolyzed to mycophenolic acid (MPA), a reversible inhibitor of inosine monophosphate dehydrogenase (IMPDH). IMPDH is a key enzyme in the de novo synthesis of guanine nucleotides, which is crucial for T- and B-lymphocyte proliferation. MPA preferentially inhibits the type II isoform of IMPDH expressed in activated lymphocytes, thereby exerting immunosuppressive effects.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between OXYCONTIN and MYCOPHENOLATE SODIUM depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of OXYCONTIN is: 10 mg orally every 12 hours; titrate based on pain severity and prior opioid exposure.. The standard adult dose of MYCOPHENOLATE SODIUM is: 720 mg orally twice daily, administered as two 360 mg tablets or two 180 mg capsules. Intravenous infusion: 720 mg intravenously over 2 hours twice daily, for patients unable to tolerate oral therapy.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between OXYCONTIN and MYCOPHENOLATE SODIUM in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. OXYCONTIN is classified as Category C. FDA Pregnancy Category C prior to 2020; no adequate studies in pregnant women. First trimester: Limited data suggest possible increased risk of neural tube defects (1.8-fold) and o. MYCOPHENOLATE SODIUM is classified as Category C. First trimester: High risk of structural malformations (e.g., cleft lip/palate, microtia, congenital heart defects) and spontaneous abortion. Second and third trimesters: Risk of o. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.